The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus

Lilly's Foundayo logs just 3,707 prescriptions in week two vs. 18,410 for Novo's oral Wegovy — a 5:1 gap that sent Lilly stock tumbling. Inhibrx surges ~39% on Merck-led takeover interest at $53/share. EU backs Sanofi's tolebrutinib for MS despite FDA rejection. FDA issues psychedelics priority review vouchers. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, bio...

FDA approves Regeneron's Otarmeni — the first gene therapy for genetic hearing loss — as Regeneron closes the 17th and final White House MFN pricing deal. Roche calls giredestrant its potentially largest product ever, Novo Nordisk's 72% decline deepens, AbbVie commits $1.4B to North Carolina. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approval...

Merck's Welireg misses in first-line RCC — Cantor challenges $2B+ peak sales. Lilly buys Kelonia for up to $7B in in vivo CAR-T push. Medicare indefinitely delays GLP-1 weight loss drug coverage pilot. Plus AstraZeneca IgAN data, Roche MOGAD results, Arrowhead upgrade. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma po...

Eli Lilly pays $3.25B upfront for Kelonia Therapeutics' invivo CAR-T platform in a deal worth up to $7B — the sixth buyout in this space since March 2025. Plus Gilead-Arcus TIGIT Phase 3 failure, Nektar's 20%+ alopecia surge, Trump's psychedelic executive order, AACR KRAS data from Revolution Medicines, and Novo Nordisk sickle cell Phase 3 results. Visit us at www.thepharmacloseout.com...

Allogene's cema-cel drives MRD negativity in 7 of 12lymphoma patients in Phase 3 Alpha3 — stock surges 50%+. Plus: Kailera's $625M biotech IPO, UCB's $1.2B Neurona acquisition for epilepsy cell therapy, Spyre'sbest-in-class UC data, Lilly Foundayo's launch metrics, and what to watch as AACR and Q1 earnings collide this week. Visit us at www.thepharmacloseout.com pharma, pharmac...

Foundayo hits MACE-4 non-inferiority (HR 0.84) as Lillytargets diabetes filing by Q2 — but FDA requests liver risk data. Plus: Cochrane review dismisses anti-amyloid Alzheimer's drugs, Daiichi Sankyo divests $1.5B consumer health unit, and Kailera's $533M obesity IPO pricesahead of tomorrow's trading. visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, b...

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The...

Daraxonrasib slashes death risk 60% in metastatic pancreaticcancer Phase 3 — Revolution Medicines leads a $1.5B offering wave. Neurocrine acquires Soleno for $2.9B, Regeneron enters radiopharma via Telix, and Travere nabs the first-ever FSGS approval with Filspari. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast...

FDA issues second CRL for Replimune's melanoma therapy RP1 —stock drops 20%, single-arm trial debate sharpens. Sun Pharma's $12B all-cash bid for Organon, Amgen's 77% proptosis response in subcutaneous TEPEZZA Phase 3, Lilly launches Foundayo, and AACR 2026 preview. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, p...

Lilly launches Foundayo to challenge Novo Nordisk in oralGLP-1s with a GoodRx access play. Gilead acquires ADC specialist Tubulis for $3.15B upfront in its third deal since February. Plus FDA lifts MacroGenics hold, AbbVie sues over 340B, and Vanda targets GLP-1 side effects with theThetis trial. www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, health...

100% tariffs on branded drug imports took effect — but thecarve-outs may matter more than the rate. Gilead acquires ADC maker Tubulis for $3.15B upfront (up to $5B), Merck launches its $6B Terns tender offer after cutting the bid by $1B on data concerns, and Novo Nordisk rolls out Wegovy HD7.2mg nationwide. Plus FDA Commissioner Makary's FY2027 budget proposals and Corbus secures its CRB-701 r...

Gilead pays $3.15B for ADC specialist Tubulis — third dealin six weeks. Neurocrine bets $2.9B on Soleno for Prader-Willi, Merck reprices Terns by $1B after data peek, and Sanofi's bispecific lunsekimig hits in asthma but misses in eczema. Plus Novo launches high-dose Wegovy. www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podca...

Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back with ORION data showing oral Wegovy's tolerability edge. Plus Biogen-Apellis, Q1's $47B M&A wave, and the first R&Dpipeline contraction in 30 years. visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical t...

Trump signs 100% tariffs on imported drugs — but exemptions create a two-tier system reshaping competitive modeling. $25.5B in pharmaM&A in eight days as R&D pipeline shrinks for first time in 30 years. Lilly's Foundayo approved, oral obesity war heats up. ORIC crashes on dose selection. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugap...

Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval as analysts project blockbuster launch. Lilly-Centessa ($6.3B) andBiogen-Apellis ($5.6B) deals cap a $25.5B acquisition spree. visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare,...

Lilly's Foundayo becomes the first oral GLP-1 approved forobesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoints in thyroid eye disease. Plus: Merck-Infinimmune $838M antibody deal, Blackstone's record $6.3B life sciences fund, and the WhiteHouse readies 100% tariffs on imported brand-name drugs. www.thepharmacloseout.com pharma, pharmaceutical, FD...

Eli Lilly acquires Centessa Pharmaceuticals for up to $7.8B,targeting narcolepsy via orexin agonists as part of pharma's $25.5B eight-day buying spree. Biogen bets $5.6B on Apellis complement therapies. FDA warns of 8deaths linked to Amgen's Tavneos liver safety signal. visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare,...

United Therapeutics' Tyvaso delivers 130.1 mL FVCimprovement in TETON-1, its second Phase 3 win in IPF — filing plans now underway. Plus Viridian's 38% stock crash on REVEAL-1 data, Lilly's $115M upfront AI deal with Insilico Medicine, BridgeBio's 54-month ATTR-CM survivaldata, Biogen's Spinraza HD FDA approval, and CBER untitled letters hitting four major companies. Visit us a...

Eli Lilly signs $2.75B biobucks deal with Insilico Medicinefor AI-discovered oral therapeutics. AAD 2026 brings 52-week ICOTYDE, zasocitinib Phase 3 psoriasis data, and Sanofi amlitelimab Q12W dosing in atopic dermatitis. Plus HI-PEITHO PE results from ACC and Merck's WINREVAIRCADENCE proof-of-concept. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech,...

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen Xolair successor, Otsuka acquires Transcend for $700M upfront, andAstraZeneca's tozorakimab delivers dual Phase 3 wins in COPD. Rocket Pharmaceuticals lands its first gene therapy approval for severe LAD-I. Visit us at: www.thepharmacloseout.c...

Wave Life Sciences plunges 58% after WVE-007 higher-doseobesity data fails to separate from lower dose. CVC Capital Partners offers €52/share ($12.6B) to take Recordati private. Plus: Kodiak's Phase 3 GLOW2 diabetic retinopathy win, Corcept's relacorilant approval in ovarian cancer, and FDA "America First" user fee pushback. Visit us at: www.thepharmacloseout.com pharma, pharmace...

Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the first biologic designed to cross the blood-brain barrier — for Hunter syndrome, and Corcept's Lifyorli (relacorilant) for platinum-resistantovarian cancer. Plus Ionis cuts Tryngolza's price 93%. Visit us at www.thepharmacloseout.com pharma, ph...

ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia. Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharm...

Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Arikayce ENCORE Phase 3b hits primary endpoint in MAC lung disease. Dizal Zegfrovy pressures J&J's Rybrevant with first-line NSCLC data. Follow us at: https://thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, h...

Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron PDUFA slips to April 10. Plus: GSK's Lynavoy, Pfizer's TALAPRO-3 data, and Genentech's emugrobart setback. Full week-in-review. pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The...